Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday

Karyopharm Therapeutics (NASDAQ:KPTI) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $37.83 million for the quarter. Karyopharm Therapeutics has set its FY 2025 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. On average, analysts expect Karyopharm Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Karyopharm Therapeutics Price Performance

KPTI opened at $9.83 on Thursday. Karyopharm Therapeutics has a fifty-two week low of $7.61 and a fifty-two week high of $25.50. The company has a market capitalization of $1.24 billion, a P/E ratio of -9.64 and a beta of 0.06. The firm’s fifty day moving average price is $0.84 and its two-hundred day moving average price is $0.82.

Analyst Ratings Changes

Several analysts have weighed in on KPTI shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Piper Sandler increased their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. HC Wainwright raised their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Karyopharm Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).